News

Please find our latest news and upcoming events below. If you are a
member of the media and have a media query please contact:

Media Queries

November 7, 2019

Inflazome Progresses Two Drugs Into Clinical Trials

Dublin (IE), Cambridge (UK), Brisbane (AU) | 07 November 2019: Inflazome (inflazome.com), the pioneering inflammasome biotech company developing multiple drugs that stop harmful inflammation, today announces that healthy volunteers have been successfully dosed in the company’s Phase I clinical trials of Inzomelid and Somalix, two small molecule inhibitors of the NLRP3 inflammasome. These trials represent an important milestone for Inflazome and confirm its leadership in the inflammasome space.

Read More
October 10, 2019

Inflazome's CSO Ranked #1 Most Cited Irish Scientist by New Citation Database

Dublin (IE), 11th September 2019: Inflazome (inflazome.com), the pioneering, clinical stage, inflammasome biotech company developing multiple small molecule drugs that inhibit harmful inflammation, is pleased to announce that our CSO, Prof. Luke O Neill has been listed as one world’s most cited scientists by a new citation metrics database. The database systematically and objectively ranks 100,000 of the globe’s most cited scientists based on their research output.

Read More
October 10, 2019

Inflazome Receives Funding from the Michael J. Fox Foundation for Parkinson's Research

  • Funding in excess of US$1 million to support the development of a brain imaging probe for patient diagnosis and the clinical development of drugs to treat neurodegenerative diseases
  • Read More

Prof. Marco Colonna M.D Joins Scientific Advisory Board

Distinguished scientist with deep expertise in innate immunity and its role in neurodegenerative diseases

Read More

Inflazome’s Drug Discovery and Development Efforts Highlighted in Nature Biotechnology News Article

Dublin (IE), Cambridge (UK) | 23 January 2019: Inflazome’s drug discovery and development efforts highlighted in Nature Biotechnology News Article.

Read More

Appointment of Dr Thomas Jung as Chief Medical Officer

Read More

Inflazome Completes €40m ($46m) Series B Financing to Develop NLRP3 Inflammasome Inhibitorsto Clinical Proof-of-Concept

  • Financing led by Forbion, with Longitude Capital and founding investors, Novartis Venture Fund and Fountain Healthcare Partners, also participating
  • Read More

Inflazome's CSO Awarded the 2018 Seymour & Vivian Milstein Award for Excellence in Interferon and Cytokine Research

Dublin (IE) | 08 May 2018: The International Cytokine and Interferon Society (ICIS) announced today that the Seymour and Vivian Milstein Award has been bestowed on two world leaders in deciphering the role of innate immunity in the host immune response. Inflazome's Chief Scientific Officer Luke O’Neill, PhD and Thirumala-Devi Kanneganti, PhD will share the 2018 Seymour and Vivian Milstein Award for Excellence in Cytokine and Interferon Research (“The Milstein Award”).

Read More

Inflazome Presents at Trinity Healthcare Entrepreneurship Forum

Dublin (IE) | 07 March 2018: Inflazome's VP Business Development Dr Jeremy Skillington joins a panel discussion at the second Trinity Healthcare Entrepreneurship Forum of the Trinity Biomedical Sciences Institute (TBSI).

Reported in The University Times: From Surgery to Startups, at TSBI

Read More

Inflazome Responds to the Cantos Trial in the New England Journal of Medicine

Dublin (IE), Cambridge (UK) | 11 January 2018: Inflazome's CSO Dr Luke O'Neill and CEO Dr Matt Cooper publish a letter to the editor in The New England Journal of Medicine (NEJM) today, commenting on the Canakinumab Antiinflammatory Thrombosis Outcome Study (CANTOS) by Ridker et al. that found reduced inflammation was associated with reduced cardiovascular risk.

Read More

Inflazome Appoints Renowned Harvard Cardiologist to its Scientific Board

Prof. Paul Ridker joins Inflazome’s Scientific Advisory Board

Read More

Inflazome's CSO Wins Trinity Provost Innovation Award

Read More

Inflazome Appoints Renowned Scientific, Industry & Clinical Experts

  • Prof. Frances Balkwill, OBE FMedSci, and Dr. David Morris join Inflazome’s Scientific Advisory Board
  • Read More

Inflazome's Chief Scientific Officer Ranked in the Top 1% of the World's Immunologists

Dublin, Ireland – 24 November, 2017 - Inflazome’s Co-Founder and Chief Scientific Officer, Professor Luke O’Neill, has been ranked in the top 1% of highly cited immunology researchers by Clarivate Analytics, a global leader in insights and analytics. Prof. O’Neill’s academic group at Trinity College Dublin works on the molecular basis of innate immunity and inflammation.

Read More

Inflazome Establishes Cambridge Office

Read More

Inflazome Expands Management Team

November 01, 2016 – Dublin, Ireland and Cambridge, UK – Inflazome, Ltd., a biotech company developing small molecule drugs that stop inflammation driven by our innate immune system, today announced the appointment of two industry leaders with extensive drug discovery and development expertise to its Management Team.

Read More

Inflazome Closes Series A Financing

Inflazome closes a $17m Series A round from Novartis Venture Fund and Fountain Healthcare Partners to develop treatments for chronic inflammatory diseases

Read More

The New Yorker Writes About Inflammation

Medical journalist Jerome Groopman writes an informative article about how medical researchers are finding that inflammation is the root cause of many of our most challenging conditions. Read the full article.

Read More

Dr Matt Cooper Interviewed by ABC News Australia

Stephanie Smail from ABC News Australia interviews Dr. Matt Cooper about how new scientific discoveries could be the key to better treatments for Alzheimer's, arthritis and MS. Read the full transcript.

Read More

The Irish Times Interviews Prof. Luke O'Neill About New Advances in Blocking Inflammation

The Irish Times interviewed Prof Luke O'Neill about his research in using small molecules to block inflammation. Early mice studies show exceptional promise in blocking multiple sclerosis, and additional tests reveal the molecules could also halt diseases such as rheumatoid arthritis and alzheimer’s. Read the full article here.

Read More

Media

If you are a member of the media and have a media query please contact:

Contact Us

Speak to us about
a better tomorrow

Contact Us

×